索拉非尼治疗中晚期肝细胞癌的疗效和不良反应

The Effects and Adverse Reaction of Sorafenib in Treating Middle and Advanced Hepatocellular Carcinoma

目的观察索拉非尼应用于中晚期肝细胞癌患者的疗效及不良反应。方法选择2013年1月至2014年12月间我院收治的中晚期肝细胞癌患者44例,随机分为对照组和观察组,每组22例。对照组患者采用替吉奥治疗,观察组患者应用索拉非尼治疗,比较两组患者的治疗效果及治疗过程中出现的不良反应。结果治疗后观察组患者疾病稳定的例数优于对照组,而不良反应的例数少于对照组,差异均具有统计学意义(P<0.05)。结论索拉非尼治疗中晚期肝细胞癌的临床效果和不良反应均优于优于替吉奥治疗,值得进一步研究和临床推广。

Objective To investigate the effect and adverse reaction of Sorafenib in treating middle and advanced hepatocellular carcinoma and to analyze its clinical significance. Methods The selected 44 advanced hepatocellular carcinoma patients in our hospital from January 2013 to December 2014 were randomly divided into control group and observation group, and there were 22 cases in each group. Patients in control group were treated with medication of S-1, while those in observation group took Sorafenib. The therapeutic effects and adverse reactions during treatment were recorded and compared. Results After treatment, more patients in observation group had their disease stable than in control group, but fewer cases had adverse reactions than in control group. The differences were statistically significant（P〈0.05）. Conclusion Sorafenib had better effects and less adverse reactions on middle and advanced hepatocellular carcinoma than S-1. It was worth of further research and clinical promotion.